| Project/Area Number |
15K18935
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
Tada Rui 東京薬科大学, 薬学部, 講師 (70635888)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 粘膜ワクチン / 真菌感染症 / リポソーム / 粘膜アジュバント / 真菌症 / DDS / Candida albicans / Aspergillus fumigatus |
|---|
| Outline of Final Research Achievements |
Mucosal vaccine systems are a promising therapeutic strategy for preventing and/or treating fungal infection, which is increasingly becoming associated with immunosuppressive conditions. We have recently found that intranasal administration of an antigenic protein with the DOTAP/DC-chol liposomes induced antigen-specific mucosal and systemic antibody responses in mice. Here, we attempted to develop a cationic liposome-based nasal vaccine against invasive fungal infections. As results, intranasal administration of DOTAP/DC-chol liposomes with CaSap2p and AfAspf3p, which are derived from Candida albicans and Aspergillus fumigatus, respectively, induced antigen-specific mucosal IgA, systemic IgG, Th17 immune responses in mice.
|
